Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ty Michael Moore
Observed name:
Ty Moore
Institutions:
The University of Kansas Cancer Center,
University of Kansas Medical Center,
Oklahoma State University Center for Health Sciences
Observed institutions:
The University of Kansas Cancer Center,
University of Kansas Medical Center,
Oklahoma State University Center for Health Sciences
ORCID:
0000-0002-3585-3287
Observed ORCID:
0000-0002-3585-3287
OpenAlex ID:
A5034948290
Factors associated with health inequities in access to kidney transplantation in the USA: A scoping review
2023
·
Zachary Ernst
, Andrew Wilson
, et al.
·
Transplantation Reviews
·
18
Discontinuation and nonpublication analysis of chronic pain randomized controlled trials
2023
·
Samuel M. Jacobsen
, Ty Moore
, et al.
·
PAIN Reports
·
12
Health inequities in human papillomavirus prevention, diagnostics and clinical care in the USA: a scoping review
2022
·
Kimberly Magana
, Laura Strand
, et al.
·
Sexually Transmitted Infections
·
9
Health inequities in dialysis care: A scoping review
2023
·
Lindsey Kay Purcell
, Joseph William Schnitker
, et al.
·
Seminars in Dialysis
·
6
Underreporting of patient-reported outcomes in cystic fibrosis randomized controlled trials using CONSORT-PRO and RoB 2.0
2022
·
Ty Moore
, Danya Nees
, et al.
·
Respiratory Medicine and Research
·
5
Reporting of Patient‐Reported Outcome Measures in Randomized Controlled Trials on Shoulder Rotator Cuff Injuries Is Suboptimal and Requires Standardization
2022
·
Lydia Brock
, Brooke Hightower
, et al.
·
Arthroscopy Sports Medicine and Rehabilitation
·
5
PDF
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice
2026
·
Sarah Blocker
, Diana Kim
, et al.
·
European Journal of Cancer
·
4
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
2025
·
Varun Jhanji
, Jacob Duncan
, et al.
·
Molecular Cancer Therapeutics
·
3
Evaluation of atezolizumab, durvalumab, lurbinectedin, and tarlatamab in high-grade extrapulmonary neuroendocrine carcinoma: A multicenter retrospective comparative analysis.
2026
·
Ty Michael Moore
, Courtney C. Cavalieri
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Health Inequities in the Epidemiology, Diagnosis, Treatment, and Outcomes of Plastic Surgery: A Scoping Review
2023
·
Ty Moore
, Danya Nees
, et al.
·
Plastic Surgery
·
2
PDF
Health Inequities in Coronary Artery Bypass Grafting Literature: A Scoping Review
2023
·
Zachariah Fisher
, Griffin Hughes
, et al.
·
Current Problems in Cardiology
·
2
An Analysis of the Evidence Informing Clinical Practice Guidelines in the Management and Treatment of Breast Cancer
2022
·
Kelsey Snider
, Ty Moore
, et al.
·
Clinical Breast Cancer
·
1
Core Outcome Set Measures Are Underreported in Breast Cancer Randomized Clinical Trials: A Cross-Sectional Study
2026
·
Alexander Douglas
, Ty Moore
, et al.
·
Clinical Breast Cancer
Atezolizumab, lurbinectedin, tarlatamab, and FOLFIRNOX in a patient with metastatic small cell carcinoma of the anal canal: A case report and review of the literature
2026
·
Ty Moore
, Austin Quick
, et al.
·
Seminars in Oncology
PDF
Analysis of corticosteroid exposure on efficacy of tarlatamab in small cell lung cancer: A multicenter retrospective study.
2026
·
Ty Michael Moore
, Courtney C. Cavalieri
, et al.
·
Journal of Clinical Oncology
Supplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
2025
·
Varun Jhanji
, Jacob Duncan
, et al.
Data from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
2025
·
Varun Jhanji
, Jacob Duncan
, et al.
Supplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
2025
·
Varun Jhanji
, Jacob Duncan
, et al.
Show more works
View as search
Works count:
18
Citation count:
69
H-index:
5
I10-index:
2
Year
Topic
Type